336 related articles for article (PubMed ID: 21457998)
1. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes.
Uber WE; Toole JM; Stroud MR; Haney JS; Lazarchick J; Crawford FA; Ikonomidis JS
J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1469-77.e2. PubMed ID: 21457998
[TBL] [Abstract][Full Text] [Related]
2. Recombinant activated factor VII in cardiac surgery: single-center experience.
Singh SP; Chauhan S; Choudhury M; Malik V; Choudhary SK
Asian Cardiovasc Thorac Ann; 2014 Feb; 22(2):148-54. PubMed ID: 24585784
[TBL] [Abstract][Full Text] [Related]
3. Intraoperative use of recombinant activated factor VII during complex aortic surgery.
Goksedef D; Panagopoulos G; Nassiri N; Levine RL; Hountis PG; Plestis KA
J Thorac Cardiovasc Surg; 2012 May; 143(5):1198-204. PubMed ID: 22285329
[TBL] [Abstract][Full Text] [Related]
4. The hazard of comparing apples and oranges: the proper indication for the use of recombinant activated clotting factor VII in cardiac surgery.
Tarzia V; Bottio T; Buratto E; Spiezia L; Simioni P; Gerosa G
J Thorac Cardiovasc Surg; 2011 Dec; 142(6):1588-9; author reply 1589. PubMed ID: 22093717
[No Abstract] [Full Text] [Related]
5. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
Bowman LJ; Uber WE; Stroud MR; Christiansen LR; Lazarchick J; Crumbley AJ; Kratz JM; Toole JM; Crawford FA; Ikonomidis JS
Ann Thorac Surg; 2008 May; 85(5):1669-76; discussion 1676-7. PubMed ID: 18442563
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery.
Brase J; Finger B; He J; Wirtz K; Stun L; McMillen R; Flynn B
Ann Thorac Surg; 2016 Jul; 102(1):35-40. PubMed ID: 26874365
[TBL] [Abstract][Full Text] [Related]
7. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
Tatoulis J; Theodore S; Meswani M; Wynne R; Hon-Yap C; Powar N
Interact Cardiovasc Thorac Surg; 2009 Sep; 9(3):459-62. PubMed ID: 19542087
[TBL] [Abstract][Full Text] [Related]
8. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Tomita E; Takase H; Tajima K; Suematsu Y
Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794
[TBL] [Abstract][Full Text] [Related]
9. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH
Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247
[TBL] [Abstract][Full Text] [Related]
10. A role for very low-dose recombinant activated factor VII in refractory bleeding after cardiac surgery: Lessons from an observational study.
Hoffmann T; Assmann A; Dierksen A; Roussel E; Ullrich S; Lichtenberg A; Albert A; Sixt S
J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1564-1573.e8. PubMed ID: 29884487
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven
Marsh K; Green D; Raco V; Papadopoulos J; Ahuja T
Ther Adv Cardiovasc Dis; 2020; 14():1753944720924255. PubMed ID: 32449469
[TBL] [Abstract][Full Text] [Related]
12. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7).
Hacquard M; Durand M; Lecompte T; Boini S; Briançon S; Carteaux JP
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1320-7. PubMed ID: 21550261
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of re-exploration for bleeding after coronary artery bypass graft surgery.
Alström U; Levin LÅ; Ståhle E; Svedjeholm R; Friberg O
Br J Anaesth; 2012 Feb; 108(2):216-22. PubMed ID: 22113929
[TBL] [Abstract][Full Text] [Related]
14. Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation.
Hollis AL; Lowery AV; Pajoumand M; Pham SM; Slejko JF; Tanaka KA; Mazzeffi M
Ann Card Anaesth; 2016; 19(3):418-24. PubMed ID: 27397445
[TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.
Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF
Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457
[TBL] [Abstract][Full Text] [Related]
16. Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.
Feih JT; Juul JJ; G Rinka JR; Baumann Kreuziger LM; Pagel PS; Tawil JN
Ann Card Anaesth; 2019; 22(4):388-393. PubMed ID: 31621674
[TBL] [Abstract][Full Text] [Related]
17. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
Pychyńska-Pokorska M; Pągowska-Klimek I; Krajewski W; Moll JJ
J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):987-94. PubMed ID: 21835642
[TBL] [Abstract][Full Text] [Related]
18. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
Guzzetta NA; Russell IA; Williams GD
Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
Chapman AJ; Blount AL; Davis AT; Hooker RL
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
[TBL] [Abstract][Full Text] [Related]
20. [Our experience with recombinant activated factor VII (NovoSeven) in the high risk cardiosurgical patients with bleeding complication].
Miskolczi S; Vaszily M; Papp C; Péterffy A
Magy Seb; 2008; 61 Suppl():45-7. PubMed ID: 18504237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
